Nanobiotix shares rose 4% to 26.80 euros around 9:20 a.m. Monday after the biotech company released Phase 1 trial data for its experimental cancer treatment JNJ-1900, also known as NBTXR3, as reported by investir.lesechos.fr.
Phase 1 Clinical Results in Advanced Melanoma
The clinical data stem from an ongoing Phase 1 trial evaluating JNJ-1900. The treatment is designed to work alongside radiotherapy in combination with an immune checkpoint inhibitor, specifically pembrolizumab or nivolumab, in patients with advanced cutaneous melanoma. Phase 1 trials primarily evaluate the safety, tolerability, feasibility, and appropriate dosage of a novel therapeutic approach.
Nanobiotix reported findings from 24 heavily pretreated patients whose advanced melanoma had progressed across multiple prior lines of therapy, including anti-PD1 treatments. According to the company’s communication, the data demonstrate an acceptable safety profile alongside preliminary signals of efficacy.
Survival Metrics and Clinical Comparisons
Patients receiving the combination therapy experienced a median progression-free survival of 6.9 months. This figure stands above the roughly three months typically documented in medical literature for comparable patient populations. Furthermore, the median overall survival reached 17.8 months, compared to an average of about one year noted in existing literature.
Invest Securities noted in a client advisory that these findings reinforce the validity of JNJ-1900 beyond its primary development track in head and neck cancers, confirming its potential as a platform therapy when combined with immunotherapy, as reported by zonebourse.com.
Financial Market Reaction and Future Trial Decisions
Following the presentation of these results at the annual congress of the European Society for Medical Oncology (ESMO) in Madrid, Spain, investor response lifted Nanobiotix shares on the Paris exchange. Financial analysts indicate that any further clinical development of JNJ-1900 in melanoma rests with Johnson & Johnson, which holds the worldwide commercial rights to the candidate and must decide whether to launch a larger randomized trial.
Frequently Asked Questions
What is the mechanism of action for JNJ-1900?
JNJ-1900 utilizes functionalized hafnium oxide nanoparticles designed to be injected directly into a tumor. When activated by external radiotherapy, these nanoparticles physically enhance the local deposition of X-ray energy inside malignant cells without increasing radiation exposure to surrounding healthy tissues.
Who holds the global rights to develop JNJ-1900?
Johnson & Johnson holds the worldwide rights to develop and commercialize the NBTXR3 platform asset. Consequently, the initiation of larger randomized clinical trials for indications like advanced melanoma depends on corporate decisions from Johnson & Johnson.
Keep reading
- Nurse Killed, Health Worker Injured in Attack While Responding to Ebola in Eastern Congo
- Study Links Mondays to Increased Heart Rhythm Vulnerability
- Iran targeting US personnel in advanced plots, memo warns (archyworldys.com)
- A 42% Cut in Melanoma Relapse Means 12 More Per 100 at Two Years (daybreakwire.com)